Lessons from the Human Genome Project that may be applicable to the Exposome Endeavor

Similar documents
Acceptance of New Technology. Richard Phillips, ExxonMobil Petroleum & Chemical CEFIC LRI 11th Annual Workshop, 19 November 2009

Developments in Chemical Toxicity Testing

Validation of the 21 st Century Toxicology Toolbox: Challenges, Opportunities, and the Way Forward

Submission to House of Lords Science and Technology Select Committee Oxford Nanopore Technologies Ltd April 2008

Visit our Career Flowchart to get more information on some of these career paths.

State strategies for bioinformatics in BRICs and the UK. Professor Brian Salter

The Impact of Genomics on Drug Development, Clinical Research, and Medical Practice

Genetics One Gene, One Phenotype

Drug Discovery and Development at NIH for Rare and Neglected Diseases September 29, 2009

Complex Adaptive Systems Forum: Transformative CAS Initiatives in Biomedicine

Integration of FDSS7000 into a modular robotic system for Open Innovation drug discovery

Frumkin, 2e Part 1: Methods and Paradigms. Chapter 6: Genetics and Environmental Health

THE FUTURE OF IN VITRO SCREENING IN THE DEVELOPMENT OF NEW DRUGS. Hajime Kojima, JaCVAM, NIHS, Japan

Stem Cell Research: Identifying emerging high priority policy issues

Lili M. Portilla, MPA Acting Director, Office of Policy, Communications and Strategic Alliances National Center for Advancing Translational Sciences

University of Pennsylvania Perelman School of Medicine High Throughput Screening Core

NIEHS and Data Integration

Nanoparticle risk assessment. practical solutions. systems toxicology

Harnessing Toxicity Testing in the 21 st Century to Help Train Chemists

dixa-a data infrastructure for chemical safety Jos Kleinjans Dept of Toxicogenomics Maastricht University

Case Study: Dr. Jonny Wray, Head of Discovery Informatics at e-therapeutics PLC

Towards a future of scientific progress without the need for experimental animals: Global trends

A NEW FIVE-YEAR PLAN FOR THE U.S. HUMAN GENOME PROJECT

Bayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms

PRESENTATION DATA. Track: Exhibitor Tutorial Session: Exhibitor Tutorial (12:30 PM 1:45 PM) Monday, February 5, :30 PM 1:45 PM Room: Room 5A

Interpreting Genome Data for Personalised Medicine. Professor Dame Janet Thornton EMBL-EBI

Insights into the Evolving Pricing & Market Access Environment

Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing

Advancing Regulatory Science at the US Food and Drug Administration

Presentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development

How Targets Are Chosen. Chris Wayman 12 th April 2012

Moving Towards Version 2.0 of Toxicity Testing in the 21 st Century and Application to Regulatory Decision Making

Prioritizing the Toxicity Testing of Environmental Chemicals at EPA

FDA Driving Biomedical Product Innovation

Human Genomics, Precision Medicine, and Advancing Human Health. The Human Genome. The Origin of Genomics : 1987

Main achievements & Progress in Gianni Dal Negro, GlaxoSmithKline Industry Co-Chair EPAA Steering Committee

DNA & Protein Synthesis. The source and the process!

Webinar IMI2 - Call 9 Data quality in preclinical research and development. Thomas Steckler IMI webinar

Bioinformatics Specialist

Advances with Acoustics

Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date

The Human Genome Project

Recent years have witnessed an expansion in the disciplines encompassing drug

Up Close and Personal

2017 Amplyus, all rights reserved

Department of Pathology and Laboratory Medicine UTHealth Medical School The Individual Development Plan for Professional Development Dec.

Open Innovation March 2014

Advances in Biomedical Research at Comenius University Bratislava

SNP GENOTYPING WITH iplex REAGENTS AND THE MASSARRAY SYSTEM

SNP GENOTYPING WITH iplex REAGENTS AND THE MASSARRAY SYSTEM

Comments on Use of Databases for Establishing the Clinical Relevance of Human Genetic Variants

Careful Transition. Getting into Business (Science) in Hungary. Janos Nacsa MD, PhD

Get to market. You want to develop medical devices that are safe, effective, and compliant. We ll show you the most efficient path.

Clearing a Path for DTC Oversight

Cellular Assays. A Strategic Market Analysis. Sample Slides

Pharmacogenetics: A SNPshot of the Future. Ani Khondkaryan Genomics, Bioinformatics, and Medicine Spring 2001

Longitudinal Population Studies Strategy

Competing & Collaborating to Achieve Successful Drug Repositioning

European Induced Pluripotent Stem Cell Bank

1.0 Background to the organisation

Re: Docket No. 2006D-0347, Federal Register: July 26, 2007 (Volume 72, Pages )

Today s Alliance Professional... Tomorrow s Strategic Leader

QIAGEN Sample & Assay Technologies From Discovery to Patient

EURL ECVAM. A broader role for greater impact. Maurice Whelan. Head of Systems Toxicology Unit and EURL ECVAM

1201 Maryland Avenue SW, Suite 900, Washington, DC ,

Why Culture Matters in Cancer Research

Translational Research

SciPhD Business Core Competencies

The Integrated Biomedical Sciences Graduate Program

Bioengineering to reduce animal use and improve drug development

Molecular Diagnostics

MODEL-BASED DRUG DEVELOPMENT: A FDA CRITICAL PATH OPPORTUNITY

How to Build a Molecular Testing Laboratory: Key Strategic & Operational Considerations. The complete guide to developing or expanding your lab

Evaluation and Regulation of Biomarkers A Public Health Perspective

Investimento & Inovação na Saúde

Intellectual property: The driving force for growth and funding

Magnis NGS Prep System. Your lab s automated library preparation solution for next-generation sequencing

Progress and Future Directions in Integrated Systems Toxicology. Mary McBride Agilent Technologies

New Paradigms in Drug Discovery: How Genomic Data are Being Used to Revolutionize the Drug Discovery and Development Process A Workshop

Toxicogenomics and Cell-Based Assays for Toxicology

BIMM 143: Introduction to Bioinformatics (Winter 2018)

The NHS approach to personalised medicine in respiratory disease. Professor Sue Chief Scientific Officer for England

Territory Account Manager (MD, NC or TX based)

Research and development case study. Human health research

The Tox21 Program. Raymond Tice, Ph.D. Chief, Biomolecular Screening Branch

WA Zebrafish Facility

Tox21: Opportunities& Challenges. Richard A. Becker Ph.D., DABT American Chemistry Council

Impact of Collaborative Robots at The Genomics Institute of the Novartis Research Foundation (GNF) Dan Sipes Novartis Foundation

Sequencing the Swine Genome: Progress and Prospects

ToxCast TM : Developing predictive signatures for chemical toxicity

Successful and Faster Drug Development through Data Mining Dirk Belmans, Ph.D. SAS Belgium

American Society for Investigative Pathology Investigating the Pathogenesis of Disease

Statements on the Regulation of Laboratory Developed Tests

HESI VALUE: Translational Safety Biomarker Assessment of Neurotoxicity Proposal

BR-9516B. SNP genotyping analysis for medium to ultra-high throughput. GENOMELAB TM SNPSTREAM GENOTYPING SERIES

Immunotoxicology Technical Committee (ITC) HESI Assembly of Members January 19, 2009

Dr Laszlo Palkonyay. World Health Organization

TRIANNI Media Kit MEDIA CONTACT CORPORATE HEADQUARTERS. Trianni, Inc. San Francisco, CA

Next G eneration Generation Microbial Microbial Genomics : The H uman Human Microbiome P roject Project George Weinstock

AN INTERNATIONAL COALITION ADVANCING A NEW PARADIGM FOR CHEMICAL SAFETY TESTING

Transcription:

Lessons from the Human Genome Project that may be applicable to the Exposome Endeavor Christopher P. Austin. M.D. Director, NIH Chemical Genomics Center Senior Advisor to the NHGRI Director for Translational Research National Institutes of Health Exposome Workshop NAS Emerging Science for Environmental Health Decisions February 26, 2010

The Ex posome

Science 300:286, 11 April 2003

Points from 2003 HGP Lessons Paper Build the best teams Process must be science-driven Meet managerial challenges International participation important Explicit milestones and quality assessment are valuable Technology matters Rapid prepublication data release demonstrates value to community Social consequences should be included as part of project (ELSI program) From Collins et al., Science 300:286, 11 April 2003

HGP Stats HGP officially launched 1990 Completion projected 2005, finished 2 years early Projected cost $3B; actual cost $2.7B Led by James Watson (1990-92), Francis Collins (1993-2003) 20 sequencing centers from 6 countries: China, France, Germany, Great Britain, Japan, U.S. Five institutions generated majority of sequence: Whitehead Institute/MIT Center for Genome Research Washington University School of Medicine Wellcome Trust Sanger Institute DOE's Joint Genome Institute Baylor College of Medicine

Importance of staging From Collins et al., Science 300:286, 11 April 2003

Stages in Deciphering the Genome 2000: First Draft 2001: Working Draft April 15, 2003: Finished reference sequence 2002-2007: Defining sequence variation in populations 2010 - : Defining individual genomes for medical purposes? 2007-2010: Defining sequence variation in a few individuals

Importance of technology From Collins et al., Science 300:286, 11 April 2003

Importance of actively managing scientific and public expectations and perceptions From Collins et al., Science 300:286, 11 April 2003

NAS Reports are very helpful but must be specific in recommendations National Research Council, 1988

Concept of a Community Resource Project A community resource project is a research project specifically devised and implemented to create a set of data, reagents or other material whose primary utility will be as a resource for the broad scientific community. Recent examples of community resource projects include the International Human Genome Sequencing Consortium, the Mouse Genome Sequencing Consortium, the Mammalian Gene Collection, the SNP Consortium, and the International HapMap Project. The products of community resource projects have, over the past several years, become increasingly important as drivers of progress in biomedical research. The scientific community will best be served if the results of community resource projects are made immediately available for free and unrestricted use by the scientific community to engage in the full range of opportunities for creative science. At the same time, it is crucial that the scientific community recognizes and respects the important contribution made by the scientists who carry out community resource projects. From: Sharing Data from Large-scale Biological Research Projects Fort Lauderdale, January 2003

A more recent lesson: Publish a project paper

Prospective community engagement is important

Consider using a Time-Risk Matrix for planning

Importance of Exposure is appreciated at NIH

A Toxicology NAS Report and Project Paper This 2007 National Academy of Science report envisions a not-so-distant future in which virtually all routine toxicity testing would be conducted in vitro in human cells or cell lines by evaluating perturbations of cellular responses in a suite of toxicity pathway assays using high throughput robotic assisted methodologies.

The Tox21 Community is becoming. Tox21 18

The Tox21 Community Tox21 19

Activities NTP NCGC EPA Historical Toxicology Data The Tox21 Community Experimental Toxicology Ultra High-Throughput Testing Mid- to High Throughput Systems Lower Organism Model System C. elegans Zebrafish In Vitro 3-D Model Systems Effect of Human/Rodent Genetic Background on Toxic Effects Computational Toxicology Validation Experience (NICEATM-ICCVAM) 21

Tox21: Organization Leadership: meets every 2 wks B. Kavlock (EPA), R. Tice (NTP), C. Austin (NCGC) Working Groups: chairs meet together every 4 wks Compounds, Assays, Informatics, Targeted Testing Co-leads from each agency Community: meets every 3 months Larger group of interested parties from 3 agencies Oversight: component Scientific Advisory Boards Reports at least once/yr

Tox21 Candidate Chemicals Universe 13,247 With structures 8,277 Plausible P-chem (logp) 7,116 Current Additional NTP 1353 ~1400 EPA 1330 ~2800 NCGC ~3000 drugs - Target library, Summer 2010 ~10,000 Sources include NTP, EPA HPV, CCL, OPPIN, OW, Inerts, ToxCast, DSSTox, EU Carcinogenomics, Pharmaceuticals, others

Lessons perhaps applicable to Exposome - 1 Large scale biology projects are now accepted and generally appreciated Some scientific questions are simply so complex, so large in scope, and/or so inherently multidisciplinary as to require a big science approach for success use HGP example Have elevator speech 2 sentences max what project is, why it s critical, what bad will happen if it s not done Team of people who WANT to collaborate is critical Ome approach requires fundamental change in thinking that is antithetical to how most science is done and most scientists are trained (and equally importantly, promoted) Expect pushback, plan for objections Address perception of drawing funds from individual investigator grants by pointing out that large scale biology projects, when designed correctly, enable individual investigators to do things they otherwise could not Data spawn entire fields of investigation, analyzing data ( expo-informatics?) and testing hypotheses generated from data analysis large scale data is hypothesis generating New technologies and companies are frequently created in course of projects and/or to address their needs Technologies become smaller/cheaper/faster under pressure from larger project and ultimately individualized - first genome $3B, next year will be $1000

Lessons perhaps applicable to Exposome - 2 Have 3 parts: data generation, technology development, informatics/data release Is inherent tension between production and techdev; ideal techdev 30% Staging is critical, with measurable outcomes, to assure all parties the scientists involved, the larger scientific community, and the funders that progress is being made and project is worthwhile Make data as freely available as possible, with as little patenting of data as possible Exposome as a community resource project Helps maintain support of community by demonstrating value Manage IP so that have diagnostic tests broadly available so don t segment measurements since they only make sense in the context of many others Include ELSI component When dealing with communities, have explicit community consultation to avoid perception of stigma Project plan must be science based, not politically based Can be difficult with big projects that require substantial ongoing political support